Dr. David Klonoff joins as a Scientific Advisory Board memberOct.16.2017
EOFLOW announces that David Klonoff, M.D. has joined EOFLOW as the latest member of its Scientific Advisory Board. Dr. Klonoff is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. He has been a Principal Investigator on 110 clinical trials of diabetes drugs and devices, and has been lead investigator on multicenter trials for Novo, Sanofi, Diasome, and Medtronic. He was the lead investigator for the first randomized controlled multicenter trial of an outpatient artificial pancreas product, and published the results in the New England Journal of Medicine. He chaired the scientific advisory board for the first FDA-cleared insulin patch pump and participated in developing the first FDA-cleared dedicated diabetes telemedicine system. Dr. Klonoff founded the Diabetes Technology Meeting, the Clinical Diabetes Technology Meeting, the International Hospital Diabetes Meeting, the Digital Diabetes Meeting, and the Medical Device Cybersecurity and Privacy Meeting.
Dr. Klonoff received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as one of the 1000 top bioengineers in the world, as well as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to participate in the White House Health and Cybersecurity Roundtable in 2015 abd to speak at the European Parliament in 2010. He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology. He has authored over 260 publications.